Related Experiment Video
Updated: May 27, 2026
09:35
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Stimulating β-cell replication and improving islet graft function by AR231453, A GPR119 agonist
1Department of Surgery and Schulze Diabetes Institute, University of Minnesota, Minneapolis, Minnesota, USA.
Transplantation Proceedings
|November 22, 2011
Summary
A GPR119 agonist, AR231453, stimulates beta-cell replication and enhances islet graft function in diabetic mice. This finding offers potential for new diabetes therapies by improving glucose control and insulin secretion.
Area of Science:
- Endocrinology
- Cell Biology
- Immunology
Background:
- G protein-coupled receptor 119 (GPR119) agonists enhance glucose-dependent insulin secretion and glucagon-like peptide 1 (GLP-1) release.
- AR231453 is a selective small-molecular GPR119 agonist with potential therapeutic applications in diabetes.
Purpose of the Study:
- To investigate the direct effects of AR231453 on beta-cell replication.
- To evaluate the impact of AR231453 on islet graft function in a mouse model of diabetes.
Main Methods:
- Syngenic mouse islets were transplanted into chemically induced diabetic mice.
- Recipients received daily bromodeoxyuridine (BrdU) with or without AR231453.
- Islet graft function was assessed by blood glucose monitoring and beta-cell replication analysis via immunofluorescence staining for insulin and BrdU.
Main Results:
- AR231453 treatment significantly accelerated normoglycemia achievement compared to vehicle control (8 ± 3 days vs. 16 ± 6 days).
- A higher percentage of insulin(+) and BrdU(+) beta cells was observed in islet grafts from AR231453-treated mice (21.5% ± 6.9% vs. 5.6% ± 3.7%).
- Plasma active GLP-1 levels were significantly elevated in AR231453-treated mice.
Conclusions:
- AR231453 directly stimulates beta-cell replication.
- AR231453 treatment improves islet graft function in diabetic mice.
- GPR119 agonism represents a promising therapeutic strategy for enhancing beta-cell function and survival.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...